Cardinal Health (NYSE: CAH) today announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19 tests through partnerships with Abbott and Quidel Corporation ("Quidel").
Beckman Coulter, a global clinical diagnostics leader, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.
Quidel has received a CE mark for its Savanna molecular testing platform and its first assay panel – the Savanna RVP4 Assay – allowing the company to market and sell the system in Europe.